Drug lookup | Fillwise

Anastrozole · DIN 02351218 · 1mg · tablet

General benefitMarketed · checked 2026-09-19

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Anastrozole · DIN 02351218 Manufacturer: Accord Healthcare Inc.; listing date 2012-12-21 Health Canada: Marketed since 2014-10-23 · brand ACH-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Accord healthcare inc · schedule Prescription

Check this DIN again · Health Canada product record

Anastrozole: Formulary list price $0.9522/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83640 · Verify on the e-Formulary ↗ (DIN 02351218)

Source record

DIN 02351218: Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id ACH Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02351218 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83640

Interchangeable products

Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522

Shortage status: resolved shortage (ended 2025-12-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02351218

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Anastrozole · DIN 02442736 · 1mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Anastrozole · DIN 02442736 Manufacturer: Sanis Health Inc.; listing date 2020-06-30 Health Canada: Marketed since 2015-07-22 · brand ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Anastrozole: Formulary list price $0.9522/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92706 · Verify on the e-Formulary ↗ (DIN 02442736)

Source record

DIN 02442736: Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id SAI Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02442736 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92706

Interchangeable products

Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442736

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Anastrozole · DIN 02529904 · 1mg · tablet

General benefitMarketed · checked 2026-09-18

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Anastrozole · DIN 02529904 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2023-08-31 Health Canada: Marketed since 2025-05-29 · brand ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Sivem pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Anastrozole: Formulary list price $0.9522/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101913 · Verify on the e-Formulary ↗ (DIN 02529904)

Source record

DIN 02529904: Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id SIV Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02529904 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101913

Interchangeable products

Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522

Shortage status: resolved shortage (ended 2025-06-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02529904

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Anastrozole · DIN 02374420 · 1mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Anastrozole · DIN 02374420 Manufacturer: Apotex Inc.; listing date 2012-12-21 Health Canada: Marketed since 2012-10-25 · brand APO-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Anastrozole: Formulary list price $0.9522/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85968 · Verify on the e-Formulary ↗ (DIN 02374420)

Source record

DIN 02374420: Apo-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id APX Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02374420 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85968

Interchangeable products

Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522

Shortage status: resolved shortage (ended 2026-01-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02374420

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Arimidex · DIN 02224135 · 1mg · tablet

General benefitMarketed · checked 2026-09-18

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Savings card: innoviCares lists Arimidex (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)

Savings card: RxHelp ONE lists ARIMIDEX (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)

1 brand, same coverage

Arimidex · DIN 02224135 Manufacturer: AstraZeneca; listing date 1996-12-19 Health Canada: Marketed since 2002-01-25 · brand ARIMIDEX · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Astrazeneca canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43395 · Verify on the e-Formulary ↗ (DIN 02224135)

Source record

DIN 02224135: Arimidex Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id AZC Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $6.3557; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02224135 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43395

Interchangeable products

Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02224135

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Co Anastrozole · DIN 02394898 · 1mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Co Anastrozole · DIN 02394898 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2012-12-21 Health Canada: Marketed since 2020-01-21 · brand TEVA-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Co Anastrozole: Formulary list price $0.9522/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88004 · Verify on the e-Formulary ↗ (DIN 02394898)

Source record

DIN 02394898: Co Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id COB Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02394898 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88004

Interchangeable products

Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522

Shortage status: resolved shortage (ended 2021-01-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02394898

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Anastrozole · DIN 02339080 · 1mg · tablet

General benefitMarketed · checked 2026-09-18

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp-Anastrozole · DIN 02339080 Manufacturer: Jamp Pharma Corporation; listing date 2013-01-29 Health Canada: Marketed since 2012-10-25 · brand JAMP-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp-Anastrozole: Formulary list price $0.9522/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82471 · Verify on the e-Formulary ↗ (DIN 02339080)

Source record

DIN 02339080: Jamp-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id JPC Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02339080 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82471

Interchangeable products

Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522

Shortage status: resolved shortage (ended 2025-06-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02339080

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Anastrozole · DIN 02379562 · 1mg · tablet

General benefitMarketed · checked 2026-09-19

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mar-Anastrozole · DIN 02379562 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2013-01-29 Health Canada: Marketed since 2012-10-25 · brand MAR-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Marcan pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mar-Anastrozole: Formulary list price $0.9522/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86544 · Verify on the e-Formulary ↗ (DIN 02379562)

Source record

DIN 02379562: Mar-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id MAR Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02379562 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86544

Interchangeable products

Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522

Shortage status: resolved shortage (ended 2019-10-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02379562

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Anastrozole · DIN 02393573 · 1mg · tablet

General benefitMarketed · checked 2026-09-19

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mint-Anastrozole · DIN 02393573 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2013-01-29 Health Canada: Marketed since 2026-06-26 · brand MINT-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Mint pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mint-Anastrozole: Formulary list price $0.9522/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87879 · Verify on the e-Formulary ↗ (DIN 02393573)

Source record

DIN 02393573: Mint-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id MIN Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02393573 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87879

Interchangeable products

Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522

Shortage status: active shortage (reported 2025-01-27, estimated to end 2026-07-30, last updated 2026-06-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02393573

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Nat-Anastrozole · DIN 02417855 · 1mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Nat-Anastrozole · DIN 02417855 Manufacturer: Natco Pharma (Canada) Inc.; listing date 2015-04-30 Health Canada: Marketed since 2015-02-03 · brand NAT-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Natco pharma (canada) inc · schedule Prescription

Check this DIN again · Health Canada product record

Nat-Anastrozole: Formulary list price $0.9522/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90247 · Verify on the e-Formulary ↗ (DIN 02417855)

Source record

DIN 02417855: Nat-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id NAT Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02417855 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90247

Interchangeable products

Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02417855

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Anastrozole · DIN 02320738 · 1mg · tablet

General benefitMarketed · checked 2026-09-18

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

PMS-Anastrozole · DIN 02320738 Manufacturer: Pharmascience Inc.; listing date 2012-12-21 Health Canada: Marketed since 2012-10-25 · brand PMS-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Pharmascience inc · schedule Prescription

Check this DIN again · Health Canada product record

PMS-Anastrozole: Formulary list price $0.9522/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80614 · Verify on the e-Formulary ↗ (DIN 02320738)

Source record

DIN 02320738: PMS-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id PMS Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02320738 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80614

Interchangeable products

Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522

Shortage status: active shortage (reported 2025-09-19, last updated 2025-09-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02320738

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Riva-Anastrozole · DIN 02392259 · 1mg · tablet

General benefitMarketed · checked 2026-09-19

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Riva-Anastrozole · DIN 02392259 Manufacturer: Laboratoire Riva Inc.; listing date 2021-08-31 Health Canada: Marketed since 2025-12-29 · brand RIVA-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Laboratoire riva inc. · schedule Prescription

Check this DIN again · Health Canada product record

Riva-Anastrozole: Formulary list price $0.9522/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87753 · Verify on the e-Formulary ↗ (DIN 02392259)

Source record

DIN 02392259: Riva-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id RIA Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02392259 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87753

Interchangeable products

Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522

Shortage status: active shortage (reported not recorded, last updated 2024-05-22) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02392259

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Anastrozole · DIN 02338467 · 1mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Anastrozole · DIN 02338467 Manufacturer: Sandoz Canada Inc.; listing date 2012-09-28 Health Canada: Marketed since 2012-07-26 · brand SANDOZ ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Anastrozole: Formulary list price $0.9522/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82412 · Verify on the e-Formulary ↗ (DIN 02338467)

Source record

DIN 02338467: Sandoz Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id SDZ Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02338467 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82412

Interchangeable products

Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522

Shortage status: resolved shortage (ended 2021-04-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02338467

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Anastrozole · DIN 02365650 · 1mg · tablet

General benefitMarketed · checked 2026-09-19

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Taro-Anastrozole · DIN 02365650 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2013-01-29 Health Canada: Marketed since 2012-10-25 · brand TARO-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Taro pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Taro-Anastrozole: Formulary list price $0.9522/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85053 · Verify on the e-Formulary ↗ (DIN 02365650)

Source record

DIN 02365650: Taro-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id TAR Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02365650 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85053

Interchangeable products

Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522

Shortage status: resolved shortage (ended 2026-06-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02365650

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Med-Anastrozole · DIN 02379104 · 1mg · tablet

General benefitDormant since 2018-03-23 · checked 2026-09-19 · What does dormant mean?

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Med-Anastrozole · DIN 02379104 Manufacturer: Generic Medical Partners Inc.; listing date 2012-12-21 Health Canada: Dormant since 2018-03-23 · brand MED-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Generic medical partners inc · schedule Prescription

Check this DIN again · Health Canada product record

Med-Anastrozole: Formulary list price $0.9522/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86499 · Verify on the e-Formulary ↗ (DIN 02379104)

Source record

DIN 02379104: Med-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id GMP Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02379104 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86499

Interchangeable products

Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02379104

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2018-03-23 — choose a marketed DIN from the same-category list.

CCP-Anastrozole · DIN 02458799 · 1mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.Discontinued 2023-08-03 · checked 2026-09-19

StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.

Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

CCP-Anastrozole · DIN 02458799 Manufacturer: CellChem Pharmaceuticals Inc.; listing date 2017-12-21 Health Canada: Cancelled post market since 2023-08-03 · brand CCP-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Cellchem pharmaceuticals inc. · schedule Prescription

Check this DIN again · Health Canada product record

CCP-Anastrozole: Formulary list price $0.9522/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94594 · Verify on the e-Formulary ↗ (DIN 02458799)

Source record

DIN 02458799: CCP-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id CCP Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02458799 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94594

Interchangeable products

Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02458799

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.

Ran-Anastrozole · DIN 02328690 · 1mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-01-22 — choose a marketed DIN from the same-category list.Discontinued 2024-01-22 · checked 2026-09-19

StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-01-22 — choose a marketed DIN from the same-category list.

Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-01-22 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Ran-Anastrozole · DIN 02328690 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2012-12-21 Health Canada: Cancelled post market since 2024-01-22 · brand RAN-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Ranbaxy pharmaceuticals canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

Ran-Anastrozole: Formulary list price $0.9522/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81420 · Verify on the e-Formulary ↗ (DIN 02328690)

Source record

DIN 02328690: Ran-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id RAN Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02328690 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81420

Interchangeable products

Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02328690

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2024-01-22 — choose a marketed DIN from the same-category list.

Look up one drug

ANASTROZOLE

Anastrozole · DIN 02351218 · 1mg · tablet

Anastrozole · DIN 02442736 · 1mg · tablet

Anastrozole · DIN 02529904 · 1mg · tablet

Apo-Anastrozole · DIN 02374420 · 1mg · tablet

Arimidex · DIN 02224135 · 1mg · tablet

Co Anastrozole · DIN 02394898 · 1mg · tablet

Jamp-Anastrozole · DIN 02339080 · 1mg · tablet

Mar-Anastrozole · DIN 02379562 · 1mg · tablet

Mint-Anastrozole · DIN 02393573 · 1mg · tablet

Nat-Anastrozole · DIN 02417855 · 1mg · tablet

PMS-Anastrozole · DIN 02320738 · 1mg · tablet

Riva-Anastrozole · DIN 02392259 · 1mg · tablet

Sandoz Anastrozole · DIN 02338467 · 1mg · tablet

Taro-Anastrozole · DIN 02365650 · 1mg · tablet

Med-Anastrozole · DIN 02379104 · 1mg · tablet

CCP-Anastrozole · DIN 02458799 · 1mg · tablet

Ran-Anastrozole · DIN 02328690 · 1mg · tablet

Matched class: 10:00 ANTINEOPLASTIC AGENTS

EXEMESTANE

LETROZOLE

ABIRATERONE ACETATE

BICALUTAMIDE

DEGARELIX ACETATE

FLUTAMIDE

FULVESTRANT

TAMOXIFEN CITRATE

ENZALUTAMIDE

ALTRETAMINE

BUSERELIN ACETATE

BUSULFAN

Availability